A new target on the horizon: a 2026 systematic review on anti-TL1A therapy for IBD

Inflammatory bowel disease — ulcerative colitis and Crohn's disease, mostly — is a long-term condition where parts of the digestive system become inflamed, with the familiar pattern of diarrhoea, urgency, bleeding, cramping and tiredness that arrive and ease in what most people just call a flare [1]. The medicines and procedures that have been built up over decades to keep that inflammation in check sit on a shelf people living with IBD know well: anti-inflammatory drugs such as aminosalicylates, short courses of corticosteroids, longer-running immunosuppressants, and an expanding row of biologic injections and small-molecule tablets — chosen by clinicians for the specific condition, its severity, and how it responds. Surgery sits behind all of that for some people when medicines do not control the disease [2].

That shelf has been growing, slowly and unevenly, for a long time. This piece is about what may eventually sit on it next — written carefully, because what may sit on it and what already does are not the same thing.

In May 2026 the Journal of Crohn's & Colitis — one of the field's specialist journals — published a systematic review with the title "TL1A as a therapeutic renaissance in inflammatory bowel disease: a systematic review from molecular mechanisms to clinical translation" [3]. The everyday-language version of the title is: a group of researchers gathered together what is currently known about a particular molecule called TL1A, traced the work from the laboratory bench through to the early clinical trials, and described where this area stands. TL1A itself is a signalling protein in the tumour necrosis factor (TNF) family — the same broad family that anti-TNF biologics already target — and laboratory work has linked it to the kind of gut inflammation seen in IBD. The drugs of interest in the review are antibodies designed to block it [3].

It is worth being careful about what kind of source a systematic review is. A systematic review is a structured summary of the existing studies on a specific question. It is more than one paper. It is not, in itself, a new randomised trial. It tells us where an area of research currently stands — what has been tried, what has been seen — but on its own it does not tell us whether a treatment built on the idea works across the population of people who would eventually receive it in routine care [4]. For an emerging therapy class, that distinction matters more than usual: the move from a promising mechanism to a medicine that improves people's lives is exactly the journey that fails most of the time, quietly, in trials we never hear about.

So the honest summary of what this 2026 review represents is something like this. It is a signal that TL1A is a serious enough idea, with enough underlying evidence, to deserve a structured stocktake from a specialist journal. It is not a signal that an anti-TL1A medicine for IBD has arrived. The drugs discussed in this kind of review are investigational — meaning their use is, at the time of writing, the business of clinical trials, not of prescriptions. Whether any of them eventually becomes a treatment for ulcerative colitis or Crohn's disease, and which patients it would help if it does, are open questions the field is still working through [3].

What is the takeaway worth carrying away, then, if you live with IBD — or care for someone who does, or work in this area? It is small, and on purpose. The treatment shelf for IBD is not closed; researchers are still actively looking for new targets, and a 2026 systematic review on TL1A is one piece of evidence that one of those searches is ongoing and taken seriously. It is not a reason to start asking for a medicine that does not yet exist as a routine option, and it is not a reason to stop or change the treatment you are currently on. What is on your shelf today, and what would be a reasonable next step if your current treatment is not enough, is a conversation that belongs with the clinicians who know your history. We're a curated information desk, not a prescription pad — for what you should actually do next, ask your IBD team.